CD20 is a cell surface protein found on B cells, a type of white blood cell involved in immune responses. CD20 is primarily targeted by monoclonal antibody therapies for the treatment of various diseases. The mechanism of action of CD20 inhibitors involves binding to the CD20 protein on B cells, leading to antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis. CD20 inhibitors are used in the treatment of several diseases, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and multiple sclerosis (MS). In RA, CD20 inhibitors are employed when conventional disease-modifying antirheumatic drugs (DMARDs) fail to achieve adequate disease control. In MS, CD20-targeted monoclonal antibodies have shown efficacy in reducing disease activity and disability progression According to WHO, non-Hodgkin lymphoma is one of the most common hematologic malignancies worldwide, with approximately 509,590 new cases and 249,100 deaths reported in Europe and the USA combined. In chronic lymphocytic leukemia, around 7,880 new cases are diagnosed each year in Europe and the USA, with an estimated mortality rate of 4,530. Rheumatoid arthritis affects approximately 0.5-1% of the adult population globally, with higher prevalence rates reported in Europe and the USA. Multiple sclerosis affects over 2.8 million people worldwide, with a significant burden in Europe and the USA.
The growth drivers of the CD20 inhibitor market include the increasing incidence and prevalence of CD20-related diseases, advancements in monoclonal antibody technology, and the expanding approval of CD20 inhibitors for new indications. Companies such as Biogen, Roche, Novartis, Servier, GSK, TG Therap, Genmab, Gilead, Fosun Pharma, Indukern, Beijing Mabworks Biotech, Dr. Reddy’s, Cellular Biomedicine, SZGIMI, Biocad, Boehringer Ingelheim, Molecular Templates, Emergent Biosolutions, Kyowa Kirin, and Pfizer cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, MSD is one such company currently conducting a clinical trial of the drug MK8808 for treating idiopathic follicular lymphoma.
Key Developments
- In May 2023, Genmab stated that they were planning a phase II trial for Rituxan non-Hodgkin’s lymphoma and follicular lymphoma in collaboration with AbbVie
- In Dec 2022, Genentech presented pharmacodynamics data of phase-III flirt trial Rituxan in follicular lymphoma at the 64th American Society of Hematology Annual Meeting and Exposition
Approved CD20 Inhibitor molecules
- Rituxan (rituximab)
- Gazyva (obinutuzumab)
- Arzerra (ofatumumab)
- Zevalin (ibritumomab tiuxetan)
- Ocrevus (ocrelizumab)
- Rituxan Hycela (rituximab, hyaluronidase)
- Kesimpta (ofatumumab subcutaneous)
- Briumvi (ublituximab)
- Lunsumio (mosunetuzumab)
- Columvi (glofitamab)
- Epkinly (epcoritamab-bysp)
- Veltucyn (veltuzumab)
- Hanlikang (rituximab biosimilar)
- Truxima (rituximab-abbs)
- Reditux (rituximab biosimilar)
- AcellBia (rituximab biosimilar)
- Rixathon (rituximab biosimilar)
- Ruxience (rituximab-pvvr)
- Anpingxi (ripertamab)
- BM-ca
- Novex (rituximab biosimilar)
- Delito (rituximab biosimilar)
- Halpryza (rituximab biosimilar)
- Kikuzubam (rituximab biosimilar)
- LCAR-AIO
- Riabni (rituximab-arrx)
- Ritucad (rituximab biosimilar)
- Anruixi (zuberitamab)
- Aurixim (rituximab conjugate)
- Maball (rituximab biosimilar)
- Mabtas (rituximab biosimilar)
- Retuxira (rituximab biosimilar)
- Ritumax (rituximab biosimilar)
- RituxiRel (rituximab biosimilar)
- Xacrel (ocrelizumab biosimilar)
- Multi-CAR-T cell therapy
CD20 Inhibitor Pipeline Molecules
- Bexxar (iodine I 131 tositumomab)
- MIL62
- Prizloncabtagene autoleucel (C-CAR039)
- 4SCAR-T
- BI 695500 (rituximab biosimilar)
- MT-3724
- PF-5230895
- TRU-015
- Divozilimab (BCD-132)
- Odronextamab (REGN1979)
- MabionCD20 (rituximab biosimilar)
- ACTR087
- C-CAR066
- DI Leu16 IL-2
- IMM0306
- JHL1101 (rituximab biosimilar)
- LY007
- MB-106
- MK-8808 (rituximab biosimilar)
- SAIT101 (rituximab biosimilar)
- TL011 (rituximab biosimilar)
- YTS101
- Zamtocabtagene autoleucel (MB-CART2019.1)
- ABP-300
- ADI-001
- B001
- F007 (rituximab biosimilar)
- GB241 (rituximab biosimilar)
- KITE-363
- LUCAR-20S CAR-T cells
- Lymphomun (FBTA05)
- MB-CART20.1
- PRO131921
- eramkafusp alfa (IGN002)
- ocaratuzumab (AME-133v)
- plamotamab (XmAb13676)
- ACE1831
- B007
- BAT4306F
- BAT4406F
- BVX-20 (rituximab biosimilar)
- CART20
- CBM-C20.1
- CC-96673
- CD20-CD19 cCAR T cells
- CHO-H01
- CM355
- CMG1A46
- CT-P53 (ocrelizumab biosimilar)
- GB261
- IMPT-314
- JMT601
- JNJ-8543
- JS203
- MBS303
- MRG001
- PBCAR 20A
- PSB202
- RG6035
- RGB 03 (rituximab biosimilar)
- SIBP-02 (rituximab biosimilar)
- TQB2825
- TRS005
- U16
- UCART20x22
- bbT369
- Imvotamab (IGM-2323)
- Nab-paclitaxel, rituximab nanoparticle (AR160)
Clinical Activity and Development of CD20 Inhibitor
In the CD20 inhibitor space, more than 50 companies are conducting more than 3000 clinical trials in this category of drugs. For instance,
- In Dec 2022, Genentech presented efficacy and adverse events data from a phase II trial of Rituxan in Mantle cell lymphoma at the 64th American Society of Hematology Annual Meeting and Exposition
- In April 2023, Novartis presented pharmacodynamics data from the phase III ALITHIOS open-label extension trial of Arzerra in Multiple sclerosis presented at 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
|
Product Name |
Total Studies |
|
Bexxar (iodine I 131 tositumomab) |
52 |
|
MIL62 |
8 |
|
Prizloncabtagene autoleucel (C-CAR039) |
7 |
|
4SCAR-T |
6 |
|
BI 695500 (rituximab biosimilar) |
5 |
|
MT-3724 |
5 |
|
PF-5230895 |
5 |
|
TRU-015 |
5 |
|
Divozilimab (BCD-132) |
5 |
|
Odronextamab (REGN1979) |
5 |
|
MabionCD20 (rituximab biosimilar) |
4 |
|
ACTR087 |
3 |
|
C-CAR066 |
3 |
|
DI Leu16 IL-2 |
3 |
|
IMM0306 |
3 |
|
JHL1101 (rituximab biosimilar) |
3 |
|
LY007 |
3 |
|
MB-106 |
3 |
|
MK-8808 (rituximab biosimilar) |
3 |
|
SAIT101 (rituximab biosimilar) |
3 |
Target Indication Analysis of CD20 Inhibitor
CD20 inhibitors are primarily indicated for the treatment of various diseases involving abnormal B-cell activity. The main target indications for CD20 inhibitors include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and multiple sclerosis (MS). In NHL and CLL, CD20-targeted monoclonal antibodies are utilized either as monotherapy or in combination with chemotherapy to target and destroy malignant B cells. In RA, CD20 inhibitors are employed when conventional disease-modifying antirheumatic drugs (DMARDs) fail to achieve desired outcomes, helping to suppress inflammation and improve joint symptoms. In MS, CD20 inhibitors have shown efficacy in reducing disease activity and disability progression by modulating the immune response and preventing B-cell infiltration into the central nervous system.
Regional Analysis of CD20 Inhibitor
CD20 Inhibitor Market
The global CD20 inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. the US market for CD20 inhibitors is robust and dynamic. The United States accounts for a significant share of the global CD20 inhibitor market due to its well-established healthcare infrastructure, extensive research and development activities, and high adoption rates of novel therapies. The market in the US is driven by factors such as the increasing prevalence of CD20-related diseases, rising awareness among healthcare professionals and patients, and the availability of reimbursement schemes for CD20 inhibitors. The growth drivers of the CD20 inhibitor market extend beyond the US, encompassing both regional and global factors. These include the growing incidence of CD20-related diseases worldwide, such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and multiple sclerosis. Additionally, advancements in monoclonal antibody technology and the development of innovative CD20 inhibitors continue to fuel market growth. The expanding approval of CD20 inhibitors for new indications also plays a crucial role in driving market expansion Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for CD20 inhibitors. These countries are increasingly adopting CD20 inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the CD20 inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the CD20 inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
CD20 inhibitors are used in the management of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and multiple sclerosis.
The growth drivers of the CD20 inhibitor market include the increasing incidence and prevalence of CD20-related diseases, advancements in monoclonal antibody technology, and the expanding approval of CD20 inhibitors for new indications
The major players in this space are Biogen, Roche, Novartis, Servier, GSK, TG Therap, Genmab, Gilead, Fosun Pharma, Indukern, Beijing Mabworks Biotech, Dr. Reddy’s, Cellular Biomedicine, SZGIMI, Biocad, Boehringer Ingelheim, Molecular Templates, Emergent Biosolutions, Kyowa Kirin, and Pfizer.
One of the key restraints of the CD20 inhibitor market is the potential for adverse side effects associated with CD20 inhibitors, such as infusion reactions and increased susceptibility to infections. Additionally, the high cost of CD20 inhibitors can pose a barrier to access for patients, limiting their widespread adoption and market growth.
- Biogen
- Roche
- Novartis
- Servier
- GSK
- TG Therap
- Genmab
- Gilead
- Fosun Pharma
- Indukern
- Beijing Mabworks Biotech
- Reddy’s
- Cellular Biomedicine
- SZGIMI
- Biocad
- Boehringer Ingelheim
- Molecular Templates
- Emergent Biosolutions
- Kyowa Kirin
- Pfizer
- Regeneron
- HB Human BioSci
- Cogent Biosci
- Sinocelltech
- Provenance
- ImmuneOnco Biopharma
- Eden Biologics
- China Biotech Services
- Fortress
- Merck (MSD)
- Elea Labs
- Archigen Biotech
- Teva
- BriSTAR Immunotech
- Miltenyi Biotec
- Abpro
- Adicet Bio
- Shanghai Pharma
- Sino Biopharm
- Lunan Pharma
- Nanjing Yoko Biomedical
- Innovent Biologics
- Probiomed
- Legend Biotech
- Trion Pharma
- Amgen
- Cadila
- Spectrum Pharma
- Mentrik
- J&J
- Acepodia
- Zhejiang Hisun
- ChemRar
- Bio-Thera Solutions
- Biocon
- Beijing Biohealthcare
- BMS
- iCell Gene Therap
- Cho Pharma
- Keymed Biosciences
- Chimagen Biosci
- Celltrion
- Walvax
- ImmPACT Bio
- CSPC Pharma
- Shanghai Junshi Biosci
- Lepu Med
- Hetero
- Intas
- Precision BioSci
- Sound Biologics
- Stada
- 3SBio
- Reliance Life Sci
- Sinopharm
- Zhejiang Teruisi Biopharma
- Shanghai Unicar
- Cellectis
- CinnaGen
- 2seventy bio
- IGM Biosciences
- Sorrento
- Zenyaku Kogyo
- Aurobindo
- R-Pharm
- Pharmaceutical Libbs
- AbbVie
- Eurofarma
- Abbott
- Kocak Farma
- Nippon Kayaku
- Fresenius Kabi
- Mabion
- Alopexx
- Sanofi
- Grupo Insud
- BIO invest
- Eli Lilly
- Nippon Shinyaku
- EMD Serono